Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 1, 1999, Pages 153-158

  Serebruany, Victor L ^a   Gurbel, Paul A ^a  

^a SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

Acute myocardial infarction; Humans; PECAM 1; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; CD31 ANTIGEN; HEPARIN; RETEPLASE;

ACUTE HEART INFARCTION; ADULT; ANTIGEN EXPRESSION; ARTICLE; BLOOD CLOT LYSIS; CIRCADIAN RHYTHM; DRUG EFFECT; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0032947755     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.1.153     Document Type: Article

References (35)

1. Newman PJ, Berndt MC, Gorsky J, White GC, Paddock LS, Muller WA. PECAM-1 (CD 31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science. 1990;247:1219-1223.
2. Muller WA, Berman ME, Newman PJ, DeLisser HM, Albelda SM. A heterophylic adhesion mechanisms for platelet/endothelial adhesion molecule 1 (CD 31 ). J Exp Med. 1992;175:1401-1404.
3. Vaporciyan AA, DeLisser HM, Yan HC, Mendiguren II, Thorn SR, Jones ML, Ward PA, Albelda SM. Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science. 1993; 262:1580-1582.
4. Muller WA, Weigl SA, Deng H, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med. 1993;178:449-460.
5. Carlos TM, Harlan JM. Leukocyte-endothelial cell adhesion molecules. Blood. 1994;84:2069-2101.
6. Cramer EM, Berger G, Berndt MC. Platelet α-granule and plasma membrane share two new components: CD9 and PECAM-1. Blood. 1994;84:1722-1730.
7. Metzelaar MJ, Korteweg J, Sixma JJ, Nieuwenhuis HK. Biochemical characterization of PECAM-1 (CD 31 antigen) on human platelets. Thromb Haemost. 1991;66:700-707.
8. Golderger A, Middleton KA, Oliver JA, Paddock C, Yan HC, DeLisser HM, Albelda SM, Newman PJ. Biosynthesis and processing of the cell adhesion molecule PECAM-1 includes production of the soluble form. J Biol Chem. 1994;269:17183-17191.
9. Ohto H, Maeda H, Shibata Y, Chen R-F, Ozaki Y, Higashihara M, Takeuchi A, Tohyama H. A novel leukocyte differentiation antigen: two monoclonal antibodies TM2 and TM3 define a 120-kD molecule present on neutrophils, monocytes, platelets and activated lymphoblasts. Blood. 1985;66:873-881.
10. Bogen S, Pak J, Garifallou M, Deng X, Muller WA. Monoclonal antibody to murine PECAM-1 (CD31 ) blocks acute inflammation in vivo. J Exp Med. 1994;179:1059-1064.
11. Gumina RJ, Schultz JE, Yao Z, Kenny D, Warltier DC, Newman PJ, Gross GJ. Antibody to platelet/endothelial cell adhesion molecule-1 reduces myocardial infarct size in a rat model of ischemia-reperfusion injury. Circulation. 1996;94:3327-3333.
12. Murohara T, Delyani JA, Albelda SM, Lefer AM. Blockade of platelet endothelial cell adhesion molecule-1 protects against myocardial ischemia and reperfusion injury in cats. J Immunol. 1996;156:3550-3557.
13. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
14. Ault KA. Flow cytometric measurement of platelet function and reticulated platelets. Ann N Y Acad Sci. 1993;677:293-308.
15. Serebruany VL, Ordonez JV, Herzog WR, Rohde M, Mortensen SA, Folkers K, Gurbel PA. Dietary coenzyme QlO supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J Cardiovasc Pharmacol. 1997;29:16-22.
16. O'Connor CM, Meese RB, McNulty S, Lucas KD, Carney RJ, LeBoeuf RM, Maddox W, Bethea CF, Shadoff N, Trahey TF, Heinsimer JA, Burks JM, O'Donnell G, Krucoff MW, Califf RM. A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction: the DUCCS-II investigators. Am J Cardiol. 1996;77:791-797.
17. 2-antiplasmin from human platelets. Blood. 1981;58:1069-1074.
18. Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation. 1989;79:920-928.
19. Eccleston D, Topol EJ. Inhibitors of platelet IIb/IIIa as augmentors of thrombolysis. Coron Artery Dis. 1995;6:947-955.
20. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol. 1993;22:381-389.
21. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, Leinbach RC. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation. 1997;95:1755-1759.
22. Faraday N, Goldschmidt-Clermont P, Dise K, Bray PF. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med. 1994;123:728-740.
23. Satoh K, Ozaki Y, Qi R, Yang L, Asazuma N, Yatomi Y, Kume S. Factors that affect the size of platelet aggregates in epinephrine induced activation: a study using the particle counting method based upon light scattering. Thromb Res. 1996;81:515-523.
24. Hoyt CH, Lerea KM. Aggregation depending signaling in human platelets is sensitive to serine/threonine phospholipase inhibitors. Biochemistry. 1995;34:9565-9570.
25. Jackson DE, Ward CM, Wang R, Newman PJ. The protein-tyrosine phosphatase SHP-2 binds platelet/endothelial cell adhesion molecule-1 (PECAM-1) and forms a distinct signaling complex during platelet aggregation: evidence for a mechanistic link between PECAM-1 and integrin-mediated cellular signaling. J Biol Chem. 1997;272:6986-6993.
26. Rosenblum WI, Nelson GH, Wormley B, Werner P, Wang J, Shih CC. Role of platelet-endothelial cell adhesion molecule (PECAM) in platelet adhesion/aggregation over injured but not denuded endothelium in vivo and ex vivo. Stroke. 1996;27:709-711.
27. Metzelaar MJ, Korteweg J, Sixma JJ, Nieuwenhuis HK. Comparison of platelet membrane markers for the detection of platelet activation in vitro and during platelet storage and cardiopulmonary bypass surgery. J Lab Clin Med. 1993;121:579-587.
28. Galinanes M, Watson C, Trivedi U, Chambers DJ, Young CP, Venn GE. Differential patterns of neutrophil adhesion molecules during cardiopulmonary bypass in humans. Circulation. 1996;94(suppl II):II-364-II-369.
29. Adreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int. 1991;8:336-351.
30. Modai I, Malmgren R, Asberg M, Beving H. Circadian rhythm of serotonin transport in human platelets. Psychopharmacology (Berl). 1986;88: 493-495.
31. 2-adrenoceptors and diurnal changes of platelet aggregability in hypertensive patients. J Hypertens. 1994;12:939-945.
32. Krulder JW, de Boer A, van den Besselaar AM, Cohen AF, Schoemaker HC, Briet E, Meinders AE. Diurnal rhythm in anticoagulant effect of heparin during a low dose constant rate infusion: a study in healthy volunteers. Thromb Haemost. 1992;68:30-32.
33. 2 and prostacyclin in urine from healthy human subjects: diurnal variation and relation to 24h excretion. Clin Sci. 1992;83:461-465.
34. Pepine CJ. Circadian variations in myocardial ischemia: implications for management. JAMA. 1991;265:386-390.
35. Manfredini R, Gallerani M, Portaluppi F, Fersini C. Relationships of the circadian rhythms of thrombotic, ischemic, hemorrhagic, and arrhythmic events to blood pressure rhythms. Ann N Y Acad Sci. 1996;783:141-158.